ENDRA Life Sciences Set to Join the Russell Microcap(R) Index

Rhea-AI Summary

ENDRA Life Sciences (NASDAQ:NDRA) is set to be added to the Russell Microcap Index, effective June 28, 2021, following a preliminary announcement on June 4. The CEO, Francois Michelon, expressed enthusiasm for this milestone, highlighting its potential to enhance the company's visibility in the investment community. Membership in this index serves as a benchmark for smaller growth stocks and facilitates automatic inclusion in various growth and value style indexes, benefiting approximately $10.6 trillion in asset benchmarks.

Positive

• Inclusion in the Russell Microcap Index may enhance visibility among investors.
• Membership can lead to automatic inclusion in various growth and value indexes.

Negative

• None.

ANN ARBOR, MI / ACCESSWIRE / June 9, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that it is expected to be added to the Russell Microcap^® Index according to a preliminary list of additions posted on June 4. The addition of ENDRA to this Index will be finalized at the conclusion of the 2021 Russell indexes annual reconstitution and, if affirmed, will be effective after the U.S. market opens on June 28.

"We are delighted that ENDRA is expected to be included in the Russell Microcap^® Index, a broadly used performance benchmark for smaller emerging growth stocks in the U.S.," stated ENDRA's Chief Executive Officer Francois Michelon. "This is an exciting milestone for ENDRA that will further raise awareness of our company within the global investment community as we advance the commercialization of our TAEUS application for the assessment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)."

Membership in the Russell Microcap^® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap^® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS^® is designed to work in concert with the over one million ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visitwww.endrainc.com.

About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

Forward-Looking Statements
All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements for ENDRA include, among others, estimates of the timing of future events and achievements, such as the expectations regarding commercializing the TAEUS^® device, establishing evaluation reference sites and initial sales in Europe, receipt of U.S. Food and Drug Administration ("FDA") regulatory approval, and expectations concerning ENDRA's business strategy, which may be affected by risks related to the impact of COVID-19 on its business plan, its ability to find and maintain development partners, market acceptance of its technology and the amount and nature of competition in its industry, its ability to protect its intellectual property, and other risks and uncertainties described in its filings with the Securities and Exchange Commission. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
YBriggs@lhai.com

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/651032/ENDRA-Life-Sciences-Set-to-Join-the-Russell-MicrocapR-Index

FAQ

What does ENDRA's inclusion in the Russell Microcap Index mean for NDRA?

Inclusion enhances ENDRA's visibility and may attract more investors, as it is a benchmark for smaller growth stocks.

When will ENDRA officially join the Russell Microcap Index?

ENDRA will officially join the Russell Microcap Index after the U.S. market opens on June 28, 2021.

How does the Russell Microcap Index impact NDRA's stock?

Inclusion in the index can improve trading liquidity and attract institutional investors, potentially positively impacting NDRA's stock price.

What is the significance of the Russell Indexes for investors?

Russell Indexes are widely used benchmarks, with around $10.6 trillion in assets tracked against them, making them significant for investors.

What technology does ENDRA Life Sciences focus on?

ENDRA is focused on Thermo Acoustic Enhanced Ultrasound (TAEUS), particularly for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).